PARIS, France, March 16, 2023 – 6:30 p.m. (CET) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage Phase 3 biotechnology company developing drugs that modulate the immune system to treat patients with inflammatory diseases chronicles, updates its 2023 financial communication schedule due to a technical adjustment of the schedule of the Abivax Board of Directors to approve the 2022 accounts and the resolutions that will be submitted to the 2023 Annual General Meeting.
The completion of an oversubscribed financing of €130 million on February 22, 2023 extended the Company’s cash position until the end of the second quarter of 2024.
Abivax reminds its investors that the Company is not exposed to liquidity problems affecting US financial institutions.